BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-77@catalystbrief.girapphe.com
DTSTAMP:20261117T061555Z
LAST-MODIFIED:20261117T061555Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Incyte Corporation — Povorcitinib [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Long-Term S
 afety and Efficacy of Povorcitinib in Participants With Moderate to Severe
  Hidradenitis Suppurativa.\nSource: https://clinicaltrials.gov/study/NCT06
 212999\nhttps://catalystbrief.girapphe.com/e/77?lang=en\nNot investment ad
 vice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/77?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
